Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLY-3+: Daclatasvir, Sofosbuvir, and Ribavirin in Genotype 3 HCV
NCT02319031Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of daclatasvir in hepatitis C (HCV), sponsored by Bristol Myers Squibb. Started Feb 2015; status: completed.
02
Drugs
daclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02319031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02319031.